Literature DB >> 19880885

Two-stage revision arthroplasty of the hip for infection using an interim articulated Prostalac hip spacer: a 10- to 15-year follow-up study.

G S Biring1, T Kostamo, D S Garbuz, B A Masri, C P Duncan.   

Abstract

We report the outcome at ten to 15 years of two-stage revision for hip infection in 99 patients using the Prostalac articulated hip spacer system. All the patients were contacted to determine their current functional and infection status using the Oxford-12, Short form-12, and Western Ontario and McMaster University Osteoarthritis Index questionnaires. A total of 11 of the 99 patients had a further infection, of whom seven responded to repeat surgery with no further sequelae. The mean interval between the stages was five months (1 to 36). We were able to review 48 living patients, with a mean age of 72 years (46 to 86), 34 (71%) of whom provided health-related quality-of-life outcome scores. The mean follow-up was 12 years (10 to 15). The long-term success rate was 89% and with additional surgery this rose to 96%. The mean global Western Ontario and McMaster University Osteoarthritis Index score was 80.6 (sd 18.3). The mean Oxford-12 score was 74.0 (sd 22.3), and the mean Short form-12 score was 53.1 (sd 9.4) (mental) and 33.5 (sd 13.5) (physical). The mean satisfaction score was 90.5 (sd 15.3). Two-stage revision for hip infection using a Prostalac interim spacer offers a predictable and lasting solution for patients with this difficult problem.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19880885     DOI: 10.1302/0301-620X.91B11.22026

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  43 in total

1.  Monitoring the one year postoperative infection rate after primary total hip replacement.

Authors:  David J Biau; Philippe Leclerc; Simon Marmor; Valerie Zeller; Wilfrid Graff; Luc Lhotellier; Philippe Leonard; Patrick Mamoudy
Journal:  Int Orthop       Date:  2011-12-30       Impact factor: 3.075

2.  A versatile hip spacer for first stage revision in prosthetic joint infection.

Authors:  R P Baker; O Borens
Journal:  Ann R Coll Surg Engl       Date:  2015-03       Impact factor: 1.891

3.  What is the Long-term Economic Societal Effect of Periprosthetic Infections After THA? A Markov Analysis.

Authors:  Thomas J Parisi; Joseph F Konopka; Hany S Bedair
Journal:  Clin Orthop Relat Res       Date:  2017-04-07       Impact factor: 4.176

4.  The Zeitgeist of Challenging the Evidence. A Perspective on the International Consensus Meeting on Periprosthetic Joint Infection.

Authors:  Hangama C Fayaz; Jesse B Jupiter
Journal:  Arch Bone Jt Surg       Date:  2017-01

5.  Culture-negative periprosthetic joint infection does not preclude infection control.

Authors:  Ronald Huang; Chi-Chien Hu; Bahar Adeli; Javad Mortazavi; Javad Parvizi
Journal:  Clin Orthop Relat Res       Date:  2012-10       Impact factor: 4.176

Review 6.  [Replacement of infected knee and hip endoprostheses].

Authors:  M Militz; V Bühren
Journal:  Chirurg       Date:  2010-04       Impact factor: 0.955

7.  CORR Insights®: Late Reinfection May Recur More Than 5 Years After Reimplantation of THA and TKA: Analysis of Pathogen Factors.

Authors:  José Cordero-Ampuero
Journal:  Clin Orthop Relat Res       Date:  2018-02       Impact factor: 4.176

8.  Late Reinfection May Recur More Than 5 Years After Reimplantation of THA and TKA: Analysis of Pathogen Factors.

Authors:  Kevin L Garvin; Ryan E Miller; Todd M Gilbert; Anthony M White; Elizabeth R Lyden
Journal:  Clin Orthop Relat Res       Date:  2018-02       Impact factor: 4.176

9.  Two-stage total hip arthroplasty: how often does it control methicillin-resistant infection?

Authors:  Fay Leung; Corey J Richards; Donald S Garbuz; Bassam A Masri; Clive P Duncan
Journal:  Clin Orthop Relat Res       Date:  2011-04       Impact factor: 4.176

10.  Are Sonication Cultures of Antibiotic Cement Spacers Useful During Second-stage Reimplantation Surgery for Prosthetic Joint Infection?

Authors:  Adam S Olsen; Alan Wilson; Michael J OʼMalley; Kenneth L Urish; Brian A Klatt
Journal:  Clin Orthop Relat Res       Date:  2018-10       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.